STOKStoke Therapeutics, Inc.

32.29USD+2.83%Mkt Cap: 2.08B $P/E:

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) …

Key Statistics

Company
Market Cap2.08B $
Enterprise Value1.74B $
Revenue (TTM)27.59M $
Gross Profit27.59M $
Net Income (TTM)-6.88M $
Revenue/Share0.4420 USD
Last Price32.29 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees170
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS86150R1077
Valuation
P/E (Trailing)
P/E (Forward)-8.99
PEG
EV/EBITDA-7.83
EV/Revenue62.93
P/S73.44
P/B5.67
EPS (TTM)-3.23
EPS (Forward)-3.49
52W Range
18.0064% of range40.22
52W High40.22 USD
52W Low18.00 USD
Profitability
Gross Margin100.00%
Oper. Margin-701.65%
EBITDA Margin0.00%
Profit Margin-3.73%
ROE-1.95%
ROA-1.65%
Growth
Revenue Growth-32.50%
Earnings Growth
Cash Flow & Leverage
Operating CF45.59M $
CapEx (TTM)670.00K $
FCF Margin-384.96%
FCF Yield-5.10%
Net Debt-290.14M $
Net Debt/EBITDA1.31
Balance Sheet
Debt/Equity0.01
Current Ratio7.69
Quick Ratio7.19
Book Value/Sh5.537 USD
Cash/Share4.538 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)47.00 USD
Upside (mean)+45.6%
Target Range35.00 USD60.00 USD
$35.00+45.6% to mean$60.00
# Analysts12
Ownership
Shares Out.64.53M
Float49.24M
Insiders3.69%
Institutions123.63%
Short Interest
Short Ratio20.2d
Short % Float25.45%
Short % Out.24.50%
Shares Short15.81M
Short (prev mo.)13.91M
Technical
SMA 5030.82 (+4.8%)
SMA 20031.58 (+2.2%)
Beta1.23
S&P 52W Chg18.16%
Avg Vol (30d)756.13K
Avg Vol (10d)853.10K
Technical Indicators
RSI (14)55.2
MACD0.5072
MACD Signal0.4309
MACD Hist.+0.0764
BB Upper34.06 USD
BB Middle31.19 USD
BB Lower28.31 USD
BB Width18.43%
ATR (14)1.649 USD
Vol Ratio (20d)1.03x